Ansa Biotechnologies

The biggest limitation in DNA synthesis isn’t cost. It’s: • Sequence rejection • Unpredictable timelines Accessing complex DNA is only half the problem. Getting it when you expect it is what keeps science moving. 📑 Read the Tech Note here: hubs.li/Q047n2hW0

Behind every shipment is a team committed to getting it right. This is the final step before orders ship under the Ansa On-Time Guarantee—helping scientists receive sequence-verified clonal DNA reliably and on schedule.

📣 Our team is excited to share that our synthetic DNA contributed to a new study in @Nature led by @arcinstitute introducing the Evo 2 genomic foundation model. 📑 Read the paper: lnkd.in/gxJS8rSJ

@BrianHie @pdhsu @Nature This would not have been possible without @AnsaBio providing the synthetic DNA. Their up to 50kb clonal DNA without any sequence restrictions is an absolute game changer!

@AnsaBio Design to delivery at speed. 🧬⚡ Synthesizing a 23 kb dystrophin plasmid in just 20 business days and pairing it with AI‑guided delivery shows how complex DNA can move rapidly from concept to application. A glimpse of the future of precision biotech.

🧭 We didn’t set out to reinvent DNA synthesis. We set out to solve a problem we experienced ourselves. Want to understand the science behind Ansa’s approach, and why enzymatic synthesis changes what’s possible? Read on: ansabio.com/blog/ansas-enz…

How fast can large, complex DNA move from design to delivery? This on-demand webinar breaks down a 23 kb dystrophin plasmid synthesized in 20 business days, and used immediately with AI-guided delivery vehicles. Watch here 👉 hubs.li/Q03Vg1SR0 #GeneTherapy #GeneSynthesis

Drug Discovery News highlights an advance from New England Bio Labs and Yale University: a synthetic phage engineering platform that enables phages to be designed and built entirely in the lab. Proud that Ansa could deliver the DNA for this study. 🔗 drugdiscoverynews.com/new-synthetic-…

ICYMI: Last week’s #JPM event sponsored by Mithrl was a packed house with sharp insights on the future of AI in biology. Leaders across pharma, biotech & AI, including Jason T. Gammack, shared what will drive the next era of therapeutic discovery. 👉 ansabio.com

End of slow science. Inside Pharma’s AI-accelerated future. #JPM2026 @johncumbers, @SynBioBeta, @mithrl_ai, @plasmidsaurus, @idtdna, @freenome, @AnsaBio, @dnanexus, @oxfordnanopore

🚀 Big news: Ansa is partnering with @idtdna to expand access to enzymatic DNA synthesis worldwide. IDT customers can now get sequence-perfect DNA constructs up to 50 kb with the speed and precision researchers trust. 🔗 hubs.ly/Q03-KKPM0

Attending #JPM26? Don’t miss this JPM Healthcare Satellite Event! 📅 Wed, Jan 14 | 5–8 PM 📍 100 Montgomery St, Ste. 1200, San Francisco Register: bit.ly/44wDkOZ Join us for Happy Hour + Panel Discussions on AI & Biopharma Innovation, featuring industry leaders, expert insights, and gourmet food & drinks. Speakers include: ✔️ Vivek Adarsh (@flyingthor), Co-Founder & CEO, @Mithrl ✔️ Mark Budde (@markwbudde), Co-Founder & CEO, @Plasmidsaurus ✔️ Rayyan Sheikh, Discovery & Innovation Research Leader, @Roche ✔️ Morten Sogaard, SVP Innovation, @AstellasUS ✔️ Steven Henck (@DNAbiotech), VP and NGS Fellow, Danaher (@idtdna) ✔️ Jimmy Lin, CSO, @freenome ✔️ Mia Nease, SVP Commercial, @dnanexus ✔️ Gordon Sanghera (@gordon_sanghera), Founder & CEO, @nanopore ✔️ Christopher Szeto (@ChrisSzetoPhD), Snr. Director of Discovery Bioinformatics, @ExelixisInc ✔️ Uli Stilz, Global BioPharma leader and Board Member ✔️ Hinco Gierman, CSO, Elephas ✔️ Jason T. Gammack (@Jason_Gammack), CEO, @AnsaBio Moderated by John Cumbers (@johncumbers) (@SynBioBeta). See you in SF! #JPMHealthcareWeek

Learn more: ansabio.com

Don't wait on slow, unreliable DNA synthesis. ✅ Order whole pathways & multi-gene systems as single constructs ✅ Tackle projects once “unsynthesizable” ✅ Design from biology-first principles w/ the confidence that constructs will arrive on time, as specified #synbio

🔎 𝗣𝗥𝗘𝗦𝗦 𝗦𝗣𝗢𝗧𝗟𝗜𝗚𝗛𝗧 We are excited to see @GenomeWeb spotlight Ansa and our mission to reshape what is possible in DNA synthesis. 👉 Read the article: hubs.li/Q03YDk7_0

What would you build with 50 kb of accurate DNA delivered in under a month? See how @ASCAppliedStem achieved a precise 50 kb knock-in using TARGATT™ + Ansa DNA synthesis. 📄 bit.ly/48KQQRD

In cell and gene therapy, one missing piece can derail your whole project. At Ansa, we deliver complex sequences like ITRs, regulatory regions & long inserts, so you can focus on function, not fabrication. 👉 lnkd.in/gfEe2h4U

Customers deserve the same confidence ordering DNA as any other reagent, says Ansa CEO @JasonTGammack. In this @SynBioBeta feature, he shares how Ansa delivers >97% fulfillment on long, complex constructs. bit.ly/4iX4qVE

𝗡𝗘𝗪 𝗔𝗗𝗗𝗜𝗧𝗜𝗢𝗡 𝗧𝗢 𝗧𝗛𝗘 𝗧𝗘𝗔𝗠: We’re thrilled to announce the appointment of Geoff Hamilton as Ansa’s new Chief Financial Officer and Chief Business Officer. 🔗 Release: hubs.li/Q03Xvjkk0 🔎 Get to know Geoff: hubs.li/Q03Xvj3H0

Sick of scaling back experiments? We were, too. That’s why we founded a company to reimagine DNA synthesis from the ground up and to fundamentally change the status quo. Experience a new kind of DNA provider: hubs.li/Q03grdRG0